

# FEDERAL REGISTER INDEX

## January–February 2014

### Food and Drug Administration

#### RULES

Administrative Detention; Corrections – 9412 (Feb 19)

Draft Guidance for Industry and Staff:

Current Good Manufacturing Practice for Medicated Feeds – 3738 (Jan 23)

Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula – 7933 (Feb 10)

Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula; Correction – 9412 (Feb 19)

Pharmacy Compounding Advisory Committee; Charter Changes – 2093 (Jan 13)

Irradiation in the Production, Processing, and Handling of Food – 10353 (Feb 25)

Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints – 6088 (Feb 3)

Medical Devices:

Classification of the Neuropsychiatric Interpretive Electroencephalograph Assessment Aid – 9083 (Feb 18)

Electronic Submission Requirements – 8832 (Feb 14)

Immunology and Microbiology Devices; Classification of John Cunningham Virus Serological Reagents – 3739 (Jan 23)

Pediatric Uses of Devices; Requirement for Submission of Information – 1735 (Jan 10)

Reports of Corrections and Removals; Technical Amendment – 9413 (Feb 19)

New Animal Drugs:

Argent Laboratories; Formalin; Tricaine Methanesulfonate; Withdrawal – 2785, 2786 (Jan 16)

Bambergmycins; Clopidol; Ivermectin; et al.; Change of Sponsor; Change of Sponsor Address – 10963 (Feb 27)

Changes of Sponsors – 10965 (Feb 27)

Zoetis Inc., et al.; Withdrawal of Approval; Combination Drug Medicated Feeds Containing an Arsenical Drug – 10974, 10976 (Feb 27)

Premarket Approvals:

Transilluminator for Breast Evaluation and Sorbent Hemoperfusion System Devices for Treatment of Hepatic Coma and Metabolic Disturbances; etc. – 3088 (Jan 17)

#### PROPOSED RULES

Draft Guidance for Industry and Staff:

Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls for Food for Animals – 6111 (Feb 3)

Demonstration of the Quality Factor Requirements for Eligible Infant Formulas; Availability – 7609 (Feb 10)

Exempt Infant Formula Production; Current Good Manufacturing Practices, Quality Control Procedures, Conduct of Audits, and Records and Reports; Availability – 7610 (Feb 10)

Focused Mitigation Strategies to Protect Food Against Intentional Adulteration; Meetings – 5353 (Jan 31)

Qualitative Risk Assessment of Risk of Activity/Animal Food Combinations for Activities (Outside the Farm Definition) Conducted in a Facility Co-Located on a Farm – 6116 (Feb 3)

Sanitary Transportation of Human and Animal Food – 7005 (Feb 5)

Food Additive Petitions; Animal Use:

Lohmann Animal Health GMBH – 7611 (Feb 10)

Generic Drug User Fee Amendments:

Regulatory Science Initiatives; Public Hearing – 10740 (Feb 26)

Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints – 6112 (Feb 3)

National Environmental Policy Act:

Tobacco Products; Categorical Exclusions – 3742 (Jan 23)

Physical Medicine Devices:

Cardiovascular Devices; Nonroller-Type Cardiopulmonary Bypass Blood Pumps for Cardiopulmonary and Circulatory Bypass; etc.;

Reclassification – 765 (Jan 7)

Premarket Approval for Shortwave Diathermy for All Other Uses;

Withdrawal – 9670 (Feb 20)

Shortwave Diathermy for All Other Uses; Reclassification – 9671 (Feb 20)

Sanitary Transportation of Human and Animal Food – 8907 (Feb 14)

#### NOTICES

Agency Information Collection Activities; Proposals, Submissions, and Approvals:

Animal Drug User Fee Act Cover Sheet – 6199 (Feb 3)

Animal Drug User Fee Act Waivers and Reductions – 10532 (Feb 25)

Animal Feed Network; State, Federal Cooperation to Prevent Spread of Pet Food and Animal Feed Related Diseases – 10529 (Feb 25)

Animal Feed Regulatory Program Standards – 9223 (Feb 18)

Animal Generic Drug User Fee Act Cover Sheet – 9224 (Feb 18)

Application for Participation in the Medical Device Fellowship Program – 3819 (Jan 23)

Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes to be Documented in Annual Reports – 9215 (Feb 18)

Color Additive Certification Requests and Recordkeeping – 7199 (Feb 6)

Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements – 10530 (Feb 25)

Current Good Manufacturing Practice; Quality System Regulation – 9908 (Feb 21)

Establishing and Maintaining Lists of United States Milk Product Manufacturers/Processors with Interest in Exporting – 9221 (Feb 18)

Evaluation of the General Market Youth Tobacco Prevention Campaign – 11112 (Feb 27)

Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile – 9219 (Feb 18)

Focus Groups as Used by the Food and Drug Administration (All FDA-Regulated Products) – 9222 (Feb 18)

Food and Drug Administration Safety Communication Readership Survey – 7677 (Feb 10)

General Licensing Provisions: Biologics License Application, Changes, etc. – 3821 (Jan 23)

Guidance for Industry and Food and Drug Administration Staff on Improving Communication of Important Safety Information – 3209 (Jan 17)

Guidance for Industry on Pharmacogenomic Data Submissions – 7198 (Feb 6)

Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables – 4350 (Jan 27)

Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice; Comment Request – 4347 (Jan 27)

Human Cells, Tissues, and Cellular and Tissue-Based Products, etc. – 3822 (Jan 23)

Human Tissue Intended for Transplantation – 9467 (Feb 19)

Information from United States Firms and Processors that Export to the European Community – 11446 (Feb 28)

Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products, etc. – 3826 (Jan 23)

Medical Devices; Third Party Review under the Food and Drug Administration Modernization Act – 9215 (Feb 18)

Over-the-Counter Human Drugs; Labeling Requirements – 9217 (Feb 18)

Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of Petitions – 7678 (Feb 10)

Potential Tobacco Product Violations Reporting Form – 9216 (Feb 18)

Premarket Approval of Medical Devices – 3210 (Jan 17)

Premarket Notification Submission 510(k) – 3210 (Jan 17)

Prescription Drug Advertisements – 11112 (Feb 27)

## Food and Drug Administration

- Protection of Human Subjects; Informed Consent; Institutional Review Boards – 3826 (Jan 23)
- Radioactive Drug Research Committees – 4348 (Jan 27)
- Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices, etc. – 3820 (Jan 23)
- Reporting and Recordkeeping for Electronic Products; General Requirements – 3210 (Jan 17)
- Requests for Feedback on Medical Device Submissions – 3821 (Jan 23)
- Risks in Direct-to-Consumer Prescription Drug Television Advertisements – 9217 (Feb 18)
- Tobacco Health Document Submission – 3820 (Jan 23)
- Voluntary Cosmetic Registration Program – 7196 (Feb 6)
- Voluntary National Retail Food Regulatory Program Standards – 6200 (Feb 3)
- Determinations that Products Were Not Withdrawn from Sale for Reasons of Safety or Effectiveness:
  - Gallium Nitrate Injectable and Five Other Drug Products – 9225 (Feb 18)
  - Valproic Acid Delayed-Release Capsules, 125 Milligrams, 250 Milligrams, and 500 Milligrams – 9225 (Feb 18)
- Draft Guidance for Industry and Staff:
  - Analgesic Indications; Developing Drug and Biological Products – 7203 (Feb 6)
  - Analytical Procedures and Methods Validation for Drugs and Biologics – 9467 (Feb 19)
  - Annual Reports for Approved Premarket Approval Applications – 7679 (Feb 10)
  - Attachment to Guidance on Antiviral Product Development; Conducting and Submitting Virology Studies to the Agency; etc. – 11448 (Feb 28)
  - Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use – 830 (Jan 7)
  - Community-Acquired Bacterial Pneumoni; Developing Drugs for Treatment – 1874 (Jan 10)
  - Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements – 2450 (Jan 14)
  - Custom Device Exemption – 2446 (Jan 14)
  - Dear Health Care Provider Letters; Improving Communication of Important Safety Information – 3827 (Jan 23)
  - Designation of High-Risk Foods for Tracing – 6596 (Feb 4)
  - Determining whether Human Research Studies can be Conducted without an Investigational New Drug Application; Reopening of the Comment Period – 7204 (Feb 6)
  - Distinguishing Liquid Dietary Supplements from Beverages – 2451 (Jan 14)
  - Enforcement Policy for Certain Tobacco Products that the Food and Drug Administration Finds Not Substantially Equivalent – 10534 (Feb 25)
  - Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies – 10814 (Feb 26)
  - Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics – 2449 (Jan 14)
  - Guidance for Industry on Special Protocol Assessment – 7676 (Feb 10)
  - International Conference on Harmonisation; E2B(R3) Electronic Transmission of Individual Case Safety Reports, etc. – 9908 (Feb 21)
  - Medical Devices Containing Materials Derived From Animal Sources – 3826 (Jan 23)
  - New Chemical Entity Exclusivity Determinations for Fixed-Combination Drug Products – 10167 (Feb 24)
  - Pediatric Studies; Sodium Nitroprusside; Summary Report, Labeling Changes – 4167 (Jan 24)
  - Providing Regulatory Submissions in Electronic Format--Standardized Study Data; Revision – 7201 (Feb 6)
  - Providing Regulatory Submissions in Electronic Format--Submissions under the Federal Food, Drug, and Cosmetic Act – 7200 (Feb 6)
  - Providing Regulatory Submissions in Electronic Format; Receipt Date; Correction – 11449 (Feb 28)
  - Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis, etc. – 1873 (Jan 10)
  - Qualification Process for Drug Development Tools – 831 (Jan 7)
  - Questions and Answers About Electronic Medical Device Reporting – 8977 (Feb 14)
  - Regulatory Submissions in Electronic Format – 7463 (Feb 7)
- Report on Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments – 9230 (Feb 18)
- Reporting of Computational Modeling Studies in Medical Device Submissions – 3211 (Jan 17)
- Requests for Feedback on Medical Device Submissions; Pre-Submission Program and Meetings with FDA Staff – 9226 (Feb 18)
- Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use – 829 (Jan 7)
- Study Data Technical Conformance Guide and Data Standards Catalog – 7204 (Feb 6)
- Submitting Food Canning Establishment Registration Form, etc., in Electronic or Paper Format – 2448 (Jan 14)
- Training Program for Regulatory Project Managers; Information Available to Industry – 9912 (Feb 21)
- Drugs for Human Use:
  - Certain Prescription Drugs Offered for Various Indications – 1875 (Jan 10)
  - Unapproved and Misbranded Oral and Injectable Drugs Labeled for Prescription Use Containing Codeine Sulfate, Codeine Phosphate, or Dihydrocodeine Bitartrate; Enforcement Action Dates – 1879 (Jan 10)
- List of Recognized Standards:
  - Recognition List Number 033; Modifications – 2453 (Jan 14)
  - Recognition List Number 034; Modifications – 4913 (Jan 30)
- Meetings:
  - Advancing the Development of Pediatric Therapeutics; Pediatric Bone Health – 7205 (Feb 6)
  - Advisory Committees; Filing of Closed Meeting Reports – 10814 (Feb 26)
  - American Glaucoma Society/Supporting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery – 6203 (Feb 3)
  - Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee – 1382 (Jan 8)
  - Anti-Infective Drugs Advisory Committee – 8462 (Feb 12)
  - Application of Physiologically-Based Pharmacokinetic Modeling to Support Dose Selection – 8192 (Feb 11)
  - Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee – 1384 (Jan 8)
  - Biofilms, Medical Devices, and Anti-Biofilm Technology; Public Workshop – 4166 (Jan 24)
  - Blood Products Advisory Committee – 9909 (Feb 21)
  - Cardiovascular and Renal Drugs Advisory Committee – 1384 (Jan 8); 1646 (Jan 9)
  - Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks in Drug Regulatory Decision-Making; Public Workshop – 1877 (Jan 10)
  - Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice; Public Workshop – 3829 (Jan 23)
  - Endocrinologic and Metabolic Drugs Advisory Committee – 9911 (Feb 21)
  - FDA/Xavier University PharmaLink Conference; Leadership in a Global Supply Chain – 9229 (Feb 18)
  - Fibromyalgia, Patient-Focused Drug Development; Rescheduling – 9468 (Feb 19)
  - Food and Drug Administration/Xavier University Global Medical Device Conference – 10815 (Feb 26)
  - Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee – 8722 (Feb 13)
  - Medical Countermeasures Initiative Regulatory Science Symposium – 9230 (Feb 18)
  - Medical Devices; The Case for Quality – 9469 (Feb 19)
  - Microbiology Devices Panel of the Medical Devices Advisory Committee – 3388 (Jan 21)
  - Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee – 6908 (Feb 5)
  - Nonprescription Drugs Advisory Committee – 1381 (Jan 8)
  - Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees – 1383 (Jan 8)
  - Over-The-Counter Drug Monograph System; Past, Present, and Future – 10168 (Feb 24)
  - Pediatric Advisory Committee – 2452 (Jan 14)
  - Pulmonary Arterial Hypertension; Patient-Focused Drug Development – 7464 (Feb 7)
  - Risk Communications Advisory Committee – 398 (Jan 3); 3830 (Jan 23)
  - Science Board – 3831 (Jan 23)
  - Science Board to the Food and Drug Administration – 1645 (Jan 9)
  - Serious Drug-Induced Liver Injury; Who Gets It? Who Doesn't? Why? – 7680 (Feb 10)

Society of Clinical Research Associates; Public Workshop – 9471 (Feb 19)  
Study Approaches and Methods to Evaluate Safety of Drugs and Biological  
Products During Pregnancy in Post-Approval Setting – 9469 (Feb 19)  
Synergizing Efforts in Standards Development for Cellular Therapies and  
Regenerative Medicine Products; Public Workshop – 8462 (Feb 12)  
Tobacco Products Scientific Advisory Committee – 9910 (Feb 21)  
Vaccines and Related Biological Products Advisory Committee – 5439  
(Jan 31); 8463 (Feb 12)

### New Drug Applications:

Improving the Quality of Abbreviated Submissions – 3828 (Jan 23)  
Phenylpropanolamine; Withdrawal of Approval – 9744 (Feb 20)

### Regulatory Review Period for Patent Extensions:

DALIRESP – 3831 (Jan 23)  
GADAVIST – 3832 (Jan 23)

### Requests for Information:

Standards for Interoperable Exchange of Information for Tracing of  
Human, Finished, Prescription Drugs, in Paper or Electronic  
Format – 9745 (Feb 20)

### Requests for Nominations:

Nonvoting Industry Representatives on Public Advisory Panels – 3390  
(Jan 21)

Nonvoting Industry Representatives on the Device Good Manufacturing  
Practice Advisory Committee – 3389 (Jan 21)

Pharmacy Compounding Advisory Committee – 2178 (Jan 13)

Pharmacy Compounding Advisory Committee, Nonvoting Industry  
Representatives – 2177 (Jan 13)

Pharmacy Compounding Advisory Committee, Voting Members – 2179  
(Jan 13)

Science Board – 6204 (Feb 3)